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SUMMARY  Alopecia areata (AA) is a heterogeneous disease charac-
terized by nonscarring hair loss on the scalp or any hair-bearing sur-
face. A wide range of clinical presentations can occur, from a single 
patch of hair loss to complete loss of hair on the scalp (alopecia totalis, 
AT) or over the entire body (alopecia universalis, AU). The cause of AA 
is unknown although most evidence supports the hypothesis that AA 
is an immunologically mediated disease. The aim of the study was to 
compare serum levels of total immunoglobulin E (IgE) between patients 
with AA and healthy subjects, and to assess the difference between 
the localized form and extensive forms of the disease such as AT and 
AU. Sixty patients with AA and 50 healthy subjects were enrolled in the 
study. Fifty patients had localized AA (LAA), and ten patients had AT, 
AU or AT/AU. Serum levels of IgE were measured using ﬂuoroenzyme 
immunoassay techniques. Serum levels of total IgE were signiﬁcantly 
higher in AA patients than in controls (p<0.05). There was no signiﬁcant 
difference in serum levels of total IgE between patients with LAA and 
those with extensive forms of the disease (p>0.05). The exact role of 
serum IgE in AA should be additionally investigated in future studies.
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INTRODUCTION
 Alopecia areata (AA) is a heterogeneous dis-
ease characterized by nonscarring hair loss on 
the scalp or any hair-bearing surface. It occurs 
in either sex, and any age can be affected. Ap-
proximately 1.7% of the population will experience 
an episode of AA during their lifetime (1). A wide 
range of clinical presentations can occur, from a 
single patch of hair loss to complete loss of hair 
on the scalp (alopecia totalis, AT) or over the en-
tire body (alopecia universalis, AU). The cause of 
AA is unknown although most evidence supports 
the hypothesis that it is an immunologically medi-
ated disease (2,3). The loss of hair is related to 
alterations in the normal cycle of hair growth. A he-
reditary component has been identiﬁed in patients 
with AA, and according to current information it is 
most likely a polygenic disease (4). The factors 
that inﬂuence the course and extent of AA are not 
known, making it impossible to predict the disease 
outcome at the time of presentation (5).
 The discovery of immunoglobulin E (IgE) and 
the development of radioimmunoassay tech-
niques for IgE estimation were major stimuli to the 
investigation of allergic diseases (6). Although se-
rum IgE concentrations are low in normal health 
condition, they are high in atopy, parasitosis (7), 
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human immunodeﬁciency virus (HIV) infection (8), 
and certain types of cancer. In some of these dis-
eases, serum IgE concentration correlated with 
the activity and intensity of the disease, and may 
be used as a prognostic factor. Serum IgE levels 
in dermatologic condition other than atopic derma-
titis usually have been reported as normal (9,10), 
although increased serum IgE concentrations 
have been documented in patients with contact 
allergic dermatitis, systemic lupus erythematosus 
(11), and psoriasis (12).
 Literature data on serum IgE in patients with 
AA are very limited and results are controversial. 
Therefore, the aim of our study was to evaluate 
serum concentrations of total IgE in AA patients 
and control subjects, and also to assess the differ-
ence between the localized and extensive forms 
of the disease such as AT and AU.
PATIENTS AND METHODS
 Patients
 The study included 60 patients with AA (32 fe-
male and 28 male, median age 32.5 years). Fam-
ily history and data on the duration and severity 
of the disease were collected. Fifty patients had 
LAA, and ten patients had AT, AU or AT/AU. The 
patients were characterized according to AA inves-
tigational assessment guidelines (13). None of the 
patients included in the study received systemic 
treatment for AA.
 Control group consisted of 50 generally healthy 
subjects (38 female and 12 male, median age 36.9 
years). They did not have any scalp lesions in their 
personal history or on clinical examination.
 The total group of AA patients and the two pa-
tient subgroups divided according to scalp hair 
loss were compared to the control group. Group 
1 (n=60) included all AA patients, group 2 (n=50) 
patients with localized AA, and group 3 (n=10) pa-
tients with AT, AU or AT/AU.
 Methods
 The levels of total IgE were determined by the 
CAP system ﬂuoroenzyme immunoassay (Phar-
macia CAP System FEIA Pharmacia Diagnostics 
AB) according to the manufacturer’s instructions. 
Results were expressed in kU/L. The assay was 
calibrated against the World Health Organization 
standard for IgE, with 2-2000 kU/L for total IgE.
 Statistical analysis
 Statistical comparisons were performed using 
χ2-test. Data were considered statistically signiﬁ-
cant at p<0.05.
RESULTS
 A total of 60 patients (32 female and 28 male) 
were examined. Family history was positive for 
AA in 5 of 60 (8.3%) patients. The duration of AA 
ranged from 1 to 168 months. Twenty-two of 60 
(36.6%) AA patients had elevated serum concen-
trations of total IgE. The range of individual IgE 
levels was wide. IgE values showed no signiﬁcant 
sex difference. There was no correlation between 
the duration of AA and serum IgE concentration. 
Concerning two subgroups of AA patients with 
extensive forms, LAA group and AT, AU or AT/AU 
group, elevated IgE levels were recorded in 18 
(36.0%) and 4 (40.0%) patients, respectively. In 
control group, 8 (16.0%) volunteers had elevated 
serum IgE levels. Serum levels of total IgE were 
signiﬁcantly higher in AA patients than in control 
subjects (p<0.05). A signiﬁcant difference was 
observed in serum levels of IgE between LAA 
patients and control group (p<0.05). In AT/AU pa-
tients, serum levels of IgE were not signiﬁcantly 
higher than those measured in controls (p>0.05). 
There was no signiﬁcant difference in IgE levels 






AA 60 22 (37)
LAA 50 18 (36)
AT, AU or AT/AU 10 4 (40)
Control group 50 8 (16)
Table 1. Serum levels of IgE in patients with AA, 
LAA, AT, UA and in control group
AA, alopecia areata; LAA, localized alopecia areata; AT, 
alopecia totalis, AU, alopecia universalis
DISCUSSION
 AA is an ancient disease that was known to 
Egyptians even in the pre-Christian time (14). 
Despite its long history, our knowledge is actually 
limited. Of the numerous pathogenic processes 
which have been proposed as the underlaying 
pathogenic causes of AA, immune, environmental 
and genetic factors (2,5,15) are the most power-
ful explanation. The possible association of serum 
IgE levels and AA has been previously reported 
(16-18). Our study clearly demonstrated that to-
tal serum IgE was signiﬁcantly increased in AA 
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patients (36.6%) in comparison to healthy subjects 
(16%). These results are consistent with a clinical 
study performed by O’Loughlin et al. (16). They 
analyzed serum IgE levels in 497 Mayo Clinic pa-
tients with various forms of dermatitis and com-
mon dermatoses, and found serum levels of IgE 
to be elevated in 30% of AA patients. Our ﬁndings 
are similar to the study of Bork et al. (17), who 
also recorded a signiﬁcant increase in serum IgE 
(32%) in children with AA. Similar results have 
been reported by Przybilla et al. (18), who found 
elevated total serum IgE in 19.7% of AA patients. 
Nevertheless, our observations of serum IgE con-
centrations in AA patients were in contrast to some 
previous studies (19,20), which did not ﬁnd an in-
crease in IgE levels.
 Accordingly, our results suggest that elevation 
of total serum IgE might be a common feature in 
AA. Unfortunately, the mechanism by which IgE 
might interact in the pathogenesis of AA is un-
known. An attractive explanation is supported by 
genetic linkage analyses, which have revealed a 
possible co-inheritance of the genetic loci. Multiple 
genetic studies on total IgE regulation have been 
performed. IgE responsiveness has recently been 
linked to a locus on chromosome 11q13 close to 
a gene encoding β-subunit of the high-afﬁnity IgE 
receptor (21). A hereditary component has also 
been identiﬁed in patients with AA, and on the ba-
sis of present information it most likely represents 
a polygenic disease (4). Tarlow et al. (22) dem-
onstrated an association between the severity of 
AA and the frequency of allele 2 of the 5 allele 
polymorphism in intron 2 of the interleukin 1 re-
ceptor antagonist gene. This allele is also asso-
ciated with severity in other chronic inﬂammatory 
disorders. Associations have also been reported 
with immunoglobulin heavy chain (Gm) and light 
chain (Km) allotypes in AA (23), raising the pos-
sibility of involvement of genes on chromosome 
2 or 14 (15). The importance of genetic factors in 
the etiology of AA is underlined by the frequency 
of positive family history in affected individuals. In 
most reports, it ranges from 10% to 20% of cases 
(15,24). There also are several reports of AA in 
twins, sometimes with concurrent onset (25).
 The evidence suggests that AA is a clinical re-
action pattern that is the result of combinations of 
genetic and environmental factors. Each of these 
factors plays a role but none, on its own, is suf-
ﬁcient to cause the disease (15). In our opinion, 
the investigation of this mechanism is very impor-
tant because it should provide information on the 
pathogenesis of AA.
CONCLUSION
 In summary, this study supports the evidence 
that elevation of total serum IgE is associated with 
AA, although this association may be limited to a 
selected patient population. Additional studies are 
clearly warranted to elucidate whether these ob-
servations represent a causal, pathogenic, or non-
causal association.
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Loosing your hair? Trilysin used every day helps! Year 1935.
(from the collection of Mr. Zlatko Puntijar)
